CN101915844A - 一种检测喹诺酮类化合物的方法及其专用量子点荧光免疫试剂盒 - Google Patents
一种检测喹诺酮类化合物的方法及其专用量子点荧光免疫试剂盒 Download PDFInfo
- Publication number
- CN101915844A CN101915844A CN2010102440864A CN201010244086A CN101915844A CN 101915844 A CN101915844 A CN 101915844A CN 2010102440864 A CN2010102440864 A CN 2010102440864A CN 201010244086 A CN201010244086 A CN 201010244086A CN 101915844 A CN101915844 A CN 101915844A
- Authority
- CN
- China
- Prior art keywords
- quantum dot
- liquid
- solution
- norfloxacin
- carbostyril compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002096 quantum dot Substances 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title claims abstract description 24
- 150000007660 quinolones Chemical class 0.000 title claims abstract description 11
- 238000003018 immunoassay Methods 0.000 title abstract description 5
- 239000000427 antigen Substances 0.000 claims abstract description 26
- 102000036639 antigens Human genes 0.000 claims abstract description 26
- 108091007433 antigens Proteins 0.000 claims abstract description 26
- 239000011248 coating agent Substances 0.000 claims abstract description 26
- 238000000576 coating method Methods 0.000 claims abstract description 26
- 239000012086 standard solution Substances 0.000 claims abstract description 16
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 8
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 8
- LISFMEBWQUVKPJ-UHFFFAOYSA-N carbostyril Natural products C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 67
- 239000007788 liquid Substances 0.000 claims description 61
- -1 carbostyril compound Chemical class 0.000 claims description 59
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical group C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims description 47
- 229960001180 norfloxacin Drugs 0.000 claims description 46
- 239000000243 solution Substances 0.000 claims description 34
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 31
- 239000000523 sample Substances 0.000 claims description 21
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 16
- 241001465754 Metazoa Species 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 238000001514 detection method Methods 0.000 claims description 14
- 239000008363 phosphate buffer Substances 0.000 claims description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 241001494479 Pecora Species 0.000 claims description 12
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims description 12
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 12
- 108010058846 Ovalbumin Proteins 0.000 claims description 11
- 210000004408 hybridoma Anatomy 0.000 claims description 11
- 229940092253 ovalbumin Drugs 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- 229940098773 bovine serum albumin Drugs 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 241000287828 Gallus gallus Species 0.000 claims description 9
- 235000015277 pork Nutrition 0.000 claims description 9
- 239000012488 sample solution Substances 0.000 claims description 9
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 claims description 9
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 8
- DPSPPJIUMHPXMA-UHFFFAOYSA-N 9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=CC(F)=C3 DPSPPJIUMHPXMA-UHFFFAOYSA-N 0.000 claims description 8
- RUXPNBWPIRDVTH-UHFFFAOYSA-N Amifloxacin Chemical compound C1=C2N(NC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 RUXPNBWPIRDVTH-UHFFFAOYSA-N 0.000 claims description 8
- QMLVECGLEOSESV-RYUDHWBXSA-N Danofloxacin Chemical compound C([C@@H]1C[C@H]2CN1C)N2C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=CC=1N2C1CC1 QMLVECGLEOSESV-RYUDHWBXSA-N 0.000 claims description 8
- BPFYOAJNDMUVBL-UHFFFAOYSA-N LSM-5799 Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3N(C)COC1=C32 BPFYOAJNDMUVBL-UHFFFAOYSA-N 0.000 claims description 8
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 claims description 8
- 229950009484 amifloxacin Drugs 0.000 claims description 8
- 229960003405 ciprofloxacin Drugs 0.000 claims description 8
- 229960004385 danofloxacin Drugs 0.000 claims description 8
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 claims description 8
- 229960002549 enoxacin Drugs 0.000 claims description 8
- 229960000702 flumequine Drugs 0.000 claims description 8
- 229960002531 marbofloxacin Drugs 0.000 claims description 8
- 229960001699 ofloxacin Drugs 0.000 claims description 8
- 229960000321 oxolinic acid Drugs 0.000 claims description 8
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 claims description 8
- 229960004236 pefloxacin Drugs 0.000 claims description 8
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000004140 cleaning Methods 0.000 claims description 7
- 229960000740 enrofloxacin Drugs 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000000502 dialysis Methods 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000013016 damping Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical class CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000012074 organic phase Substances 0.000 claims description 4
- 238000002203 pretreatment Methods 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 235000009518 sodium iodide Nutrition 0.000 claims description 3
- 108060003552 hemocyanin Proteins 0.000 claims description 2
- WKOVRQFUCLHTHB-UHFFFAOYSA-N n-(ethyliminomethylideneamino)-n-methylmethanamine Chemical class CCN=C=NN(C)C WKOVRQFUCLHTHB-UHFFFAOYSA-N 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 8
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 3
- 238000012544 monitoring process Methods 0.000 abstract description 2
- 238000012216 screening Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 15
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000006143 cell culture medium Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 description 4
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 4
- 239000001103 potassium chloride Substances 0.000 description 4
- 235000011164 potassium chloride Nutrition 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000010612 desalination reaction Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- CUMCMYMKECWGHO-UHFFFAOYSA-N 3-methyl-1,2-oxazole Chemical compound CC=1C=CON=1 CUMCMYMKECWGHO-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940018557 citraconic acid Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010244086 CN101915844B (zh) | 2010-08-03 | 2010-08-03 | 一种检测喹诺酮类化合物的方法及其专用量子点荧光免疫试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201010244086 CN101915844B (zh) | 2010-08-03 | 2010-08-03 | 一种检测喹诺酮类化合物的方法及其专用量子点荧光免疫试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101915844A true CN101915844A (zh) | 2010-12-15 |
CN101915844B CN101915844B (zh) | 2013-06-26 |
Family
ID=43323405
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201010244086 Expired - Fee Related CN101915844B (zh) | 2010-08-03 | 2010-08-03 | 一种检测喹诺酮类化合物的方法及其专用量子点荧光免疫试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101915844B (zh) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102206279A (zh) * | 2011-03-25 | 2011-10-05 | 商务部流通产业促进中心 | 检测恩诺沙星的scFv抗体、其编码基因及应用 |
CN102353785A (zh) * | 2011-07-06 | 2012-02-15 | 清华大学深圳研究生院 | 一种基于量子点的免疫荧光检测恩诺沙星的方法及专用试剂盒 |
CN102928597A (zh) * | 2012-10-30 | 2013-02-13 | 北京维德维康生物技术有限公司 | 同时检测磺胺类和喹诺酮类药物的elisa方法及其试剂盒 |
CN103018453A (zh) * | 2011-09-20 | 2013-04-03 | 北京勤邦生物技术有限公司 | 一种喹诺酮类药物的化学发光酶联免疫检测试剂盒 |
CN103175961A (zh) * | 2013-03-12 | 2013-06-26 | 中国农业大学 | 用于检测21种磺胺药物和11种喹喏酮药物的酶联免疫试剂盒及其应用 |
CN105622506A (zh) * | 2016-01-04 | 2016-06-01 | 河北北方学院 | 一种丙氨环丙沙星半抗原及其制备方法和用途 |
CN105628929A (zh) * | 2014-11-25 | 2016-06-01 | 北京维德维康生物技术有限公司 | 同时检测庆大霉素和喹诺酮类药物的量子点免疫荧光试剂盒 |
CN105622505A (zh) * | 2016-01-04 | 2016-06-01 | 河北北方学院 | 一种丙酸环丙沙星抗原的合成 |
CN106083890A (zh) * | 2016-07-04 | 2016-11-09 | 北京明日达科技发展有限责任公司 | 一种氧氟沙星半抗原制备方法及其应用 |
CN107490565A (zh) * | 2017-06-27 | 2017-12-19 | 昆明理工大学 | 一种氮掺杂碳量子点荧光增敏检测环丙沙星的方法 |
CN107515206A (zh) * | 2017-06-27 | 2017-12-26 | 昆明理工大学 | 一种硫掺杂碳量子点荧光增敏检测诺氟沙星的方法 |
CN108709992A (zh) * | 2018-05-30 | 2018-10-26 | 中国烟草总公司郑州烟草研究院 | 一种检测黄樟素的酶联免疫试剂盒及其应用 |
CN108931646A (zh) * | 2018-05-30 | 2018-12-04 | 中国烟草总公司郑州烟草研究院 | 一种检测黄樟素的试纸条及其制备方法和应用 |
CN113433102A (zh) * | 2021-06-09 | 2021-09-24 | 郑州大学第二附属医院 | 一种荧光碳点及其制备的检测环丙沙星的荧光试剂盒 |
CN114252419A (zh) * | 2021-12-02 | 2022-03-29 | 江南大学 | 一种使用藻蓝蛋白作为荧光探针的环丙沙星检测方法 |
CN117871486A (zh) * | 2024-01-08 | 2024-04-12 | 生态环境部华南环境科学研究所(生态环境部生态环境应急研究所) | 基于卵清蛋白-金纳米簇的喹诺酮类药物荧光检测方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1811436A (zh) * | 2006-02-16 | 2006-08-02 | 中国农业大学 | 一种检测恩诺沙星的方法及其专用酶联免疫试剂盒 |
CN101173925A (zh) * | 2007-11-09 | 2008-05-07 | 北京望尔生物技术有限公司 | 一种检测喹诺酮类药物残留的胶体金试纸卡 |
CN101762706A (zh) * | 2010-01-05 | 2010-06-30 | 中国农业大学 | 一种检测对人体有害的小分子物质残留的方法及其专用试剂盒 |
-
2010
- 2010-08-03 CN CN 201010244086 patent/CN101915844B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1811436A (zh) * | 2006-02-16 | 2006-08-02 | 中国农业大学 | 一种检测恩诺沙星的方法及其专用酶联免疫试剂盒 |
CN101173925A (zh) * | 2007-11-09 | 2008-05-07 | 北京望尔生物技术有限公司 | 一种检测喹诺酮类药物残留的胶体金试纸卡 |
CN101762706A (zh) * | 2010-01-05 | 2010-06-30 | 中国农业大学 | 一种检测对人体有害的小分子物质残留的方法及其专用试剂盒 |
Non-Patent Citations (5)
Title |
---|
ANNE-CATHERINE HUET ET AL.: "Simultaneous Determination of (Fluoro)quinolone Antibiotics in Kidney, Marine Products, Eggs, and Muscle by Enzyme-Linked Immunosorbent Assay (ELISA)", 《J. AGRIC. FOOD CHEM.》 * |
JUNXIA CHEN ET AL.: "A novel quantum dot-based fluoroimmunoassay method for detection of Enrofloxacin residue in chicken muscle tissue", 《FOOD CHEMISTRY》 * |
SHERYL A. TITTLEMIER ET AL.: "Development of a Direct Competitive Enzyme-Linked Immunosorbent Assay for the Detection of Fluoroquinolone Residues in Shrimp", 《FOOD ANALYTICAL METHODS》 * |
ZHANHUI WANG ET AL.: "Development of a Monoclonal Antibody-Based Broad-Specificity ELISA for Fluoroquinolone Antibiotics in Foods and Molecular Modeling Studies of Cross-Reactive Compounds", 《ANAL. CHEM.》 * |
王战辉 等: "喹诺酮类药物抗体制备研究进展及策略分析", 《中国农业科学》 * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102206279A (zh) * | 2011-03-25 | 2011-10-05 | 商务部流通产业促进中心 | 检测恩诺沙星的scFv抗体、其编码基因及应用 |
CN102206279B (zh) * | 2011-03-25 | 2013-08-28 | 商务部流通产业促进中心 | 检测恩诺沙星的scFv抗体、其编码基因及应用 |
CN102353785A (zh) * | 2011-07-06 | 2012-02-15 | 清华大学深圳研究生院 | 一种基于量子点的免疫荧光检测恩诺沙星的方法及专用试剂盒 |
CN102353785B (zh) * | 2011-07-06 | 2013-11-06 | 清华大学深圳研究生院 | 一种基于量子点的免疫荧光检测恩诺沙星的方法及专用试剂盒 |
CN103018453A (zh) * | 2011-09-20 | 2013-04-03 | 北京勤邦生物技术有限公司 | 一种喹诺酮类药物的化学发光酶联免疫检测试剂盒 |
CN103018453B (zh) * | 2011-09-20 | 2015-08-12 | 北京勤邦生物技术有限公司 | 一种喹诺酮类药物的化学发光酶联免疫检测试剂盒 |
CN102928597A (zh) * | 2012-10-30 | 2013-02-13 | 北京维德维康生物技术有限公司 | 同时检测磺胺类和喹诺酮类药物的elisa方法及其试剂盒 |
CN102928597B (zh) * | 2012-10-30 | 2015-06-10 | 北京维德维康生物技术有限公司 | 同时检测磺胺类和喹诺酮类药物的elisa方法及其试剂盒 |
CN103175961A (zh) * | 2013-03-12 | 2013-06-26 | 中国农业大学 | 用于检测21种磺胺药物和11种喹喏酮药物的酶联免疫试剂盒及其应用 |
CN105628929A (zh) * | 2014-11-25 | 2016-06-01 | 北京维德维康生物技术有限公司 | 同时检测庆大霉素和喹诺酮类药物的量子点免疫荧光试剂盒 |
CN105622506A (zh) * | 2016-01-04 | 2016-06-01 | 河北北方学院 | 一种丙氨环丙沙星半抗原及其制备方法和用途 |
CN105622505A (zh) * | 2016-01-04 | 2016-06-01 | 河北北方学院 | 一种丙酸环丙沙星抗原的合成 |
CN106083890A (zh) * | 2016-07-04 | 2016-11-09 | 北京明日达科技发展有限责任公司 | 一种氧氟沙星半抗原制备方法及其应用 |
CN107490565A (zh) * | 2017-06-27 | 2017-12-19 | 昆明理工大学 | 一种氮掺杂碳量子点荧光增敏检测环丙沙星的方法 |
CN107515206A (zh) * | 2017-06-27 | 2017-12-26 | 昆明理工大学 | 一种硫掺杂碳量子点荧光增敏检测诺氟沙星的方法 |
CN107515206B (zh) * | 2017-06-27 | 2019-11-08 | 昆明理工大学 | 一种硫掺杂碳量子点荧光增敏检测诺氟沙星的方法 |
CN107490565B (zh) * | 2017-06-27 | 2019-12-03 | 昆明理工大学 | 一种氮掺杂碳量子点荧光增敏检测环丙沙星的方法 |
CN108709992A (zh) * | 2018-05-30 | 2018-10-26 | 中国烟草总公司郑州烟草研究院 | 一种检测黄樟素的酶联免疫试剂盒及其应用 |
CN108931646A (zh) * | 2018-05-30 | 2018-12-04 | 中国烟草总公司郑州烟草研究院 | 一种检测黄樟素的试纸条及其制备方法和应用 |
CN108709992B (zh) * | 2018-05-30 | 2021-03-09 | 中国烟草总公司郑州烟草研究院 | 一种检测黄樟素的酶联免疫试剂盒及其应用 |
CN108931646B (zh) * | 2018-05-30 | 2021-04-27 | 中国烟草总公司郑州烟草研究院 | 一种检测黄樟素的试纸条及其制备方法和应用 |
CN113433102A (zh) * | 2021-06-09 | 2021-09-24 | 郑州大学第二附属医院 | 一种荧光碳点及其制备的检测环丙沙星的荧光试剂盒 |
CN114252419A (zh) * | 2021-12-02 | 2022-03-29 | 江南大学 | 一种使用藻蓝蛋白作为荧光探针的环丙沙星检测方法 |
CN117871486A (zh) * | 2024-01-08 | 2024-04-12 | 生态环境部华南环境科学研究所(生态环境部生态环境应急研究所) | 基于卵清蛋白-金纳米簇的喹诺酮类药物荧光检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101915844B (zh) | 2013-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101915844B (zh) | 一种检测喹诺酮类化合物的方法及其专用量子点荧光免疫试剂盒 | |
CN100403030C (zh) | 检测苏丹红药物的酶联免疫试剂盒及方法 | |
CN100501409C (zh) | 一种检测动物源性食品中氯霉素类药物的酶联免疫试剂盒 | |
CN101907623B (zh) | 一种检测庆大霉素和/或小诺霉素的方法及其专用量子点荧光免疫试剂盒 | |
CN102967709B (zh) | 检测玉米赤霉烯酮药物的酶联免疫试剂盒及其应用 | |
CN101936985B (zh) | 一种检测己烯雌酚的方法及其专用化学发光免疫试剂盒 | |
CN101571539A (zh) | 检测头孢类药物的酶联免疫试剂盒及其应用 | |
CN101776685B (zh) | 检测三甲氧苄胺嘧啶药物的酶联免疫试剂盒及其应用 | |
CN105785012B (zh) | 检测利巴韦林的酶联免疫试剂盒及其应用 | |
CN102928597B (zh) | 同时检测磺胺类和喹诺酮类药物的elisa方法及其试剂盒 | |
CN101299045B (zh) | 检测氟苯尼考及氟苯尼考胺的方法及其专用酶联免疫试剂盒 | |
CN102079789A (zh) | 一种检测马杜霉素的方法及其专用酶联免疫试剂盒 | |
CN101915845A (zh) | 一种检测莱克多巴胺的方法及其专用化学发光免疫试剂盒 | |
CN101936984B (zh) | 一种检测克伦特罗的方法及其专用化学发光免疫试剂盒 | |
CN101936986B (zh) | 一种检测地西泮的方法及其专用化学发光免疫试剂盒 | |
CN101936983B (zh) | 一种检测磺胺类化合物的方法及其专用量子点荧光免疫试剂盒 | |
CN103018451B (zh) | 检测氯霉素的酶联免疫试剂盒及其应用 | |
CN103364553A (zh) | 检测硝基咪唑类药物的酶联免疫试剂盒及其应用 | |
CN105628929A (zh) | 同时检测庆大霉素和喹诺酮类药物的量子点免疫荧光试剂盒 | |
CN101995460B (zh) | 莱克多巴胺残留的时间分辨免疫分析检测试剂盒及其检测方法 | |
CN104950105A (zh) | 氯霉素半抗原和抗原的制备方法及其在化学发光免疫试剂盒中的应用 | |
CN101093225A (zh) | 一种微囊藻毒素酶联免疫检测试剂盒 | |
CN100492009C (zh) | 检测氟甲喹药物的酶联免疫试剂盒及方法 | |
CN105017347A (zh) | 庆大霉素半抗原及其制备方法和应用 | |
CN104569398B (zh) | 检测乙氧基喹啉的酶联免疫试剂盒及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Shen Jianzhong Inventor after: Wu Congming Inventor after: Zhang Suxia Inventor after: Wang Zhanhui Inventor after: Shi Weimin Inventor after: Cheng Linli Inventor after: Cao Xingyuan Inventor after: Tang Shusheng Inventor before: Wu Congming Inventor before: Shen Jianzhong Inventor before: Zhang Suxia Inventor before: Wang Zhanhui Inventor before: Shi Weimin Inventor before: Cheng Linli Inventor before: Cao Xingyuan Inventor before: Tang Shusheng |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WU CONGMING SHEN JIANZHONG ZHANG SUXIA WANG ZHANHUI SHI WEIMIN CHENG LINLI CAO XINGYUAN TANG SHUSHENG TO: SHEN JIANZHONG WU CONGMING ZHANG SUXIA WANG ZHANHUI SHI WEIMIN CHENG LINLI CAO XINGYUAN TANG SHUSHENG |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130626 |
|
CF01 | Termination of patent right due to non-payment of annual fee |